Dupilumab combined with corticosteroid therapy for Kimura disease with multiple systemic masses: a case report and literature review

  • 0Department of Dermatology, Shenzhen University General Hospital, Shenzhen, Shenzhen, China.

|

|

Summary

This summary is machine-generated.

This study shows dupilumab combined with corticosteroids effectively treats Kimura's disease (KD) in a patient with atopic dermatitis. The treatment reduced nodules and key allergy markers, offering a potential new strategy for this rare condition.

Area Of Science

  • Dermatology
  • Immunology
  • Rare Diseases

Background

  • Kimura's disease (KD) pathogenesis is unclear, lacking unified diagnostic criteria and optimal treatments.
  • Clinical presentation of KD is heterogeneous, complicating diagnosis and management.
  • This case involves a rare presentation of KD with concurrent atopic dermatitis.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents 01:29

142

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids 01:21

96

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF 01:24

117

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management 01:29

114

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Tumor Immunotherapy 01:27

480

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.